Clinical trial
A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With…
NCT00112281 · Arginox Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00112281 |
|---|---|
| Title | A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack |
| Official title | A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the… |
| Lead sponsor | Arginox Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Shock, Cardiogenic |
| Intervention type | Drug |
| Interventions | Tilarginine Acetate Injection intravenous infusion |
| Enrollment | 658 |
| Start date | May 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Jun 2, 2005 |
| Last update posted | Aug 4, 2006 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: